Učitavanje...
The Preclinical Discovery and Development of Bortezomib for the Treatment of Mantle Cell Lymphoma
INTRODUCTION: Mantle cell lymphoma (MCL) is an incurable, often aggressive B-cell malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and approved for treatment of relapsed refractory multiple myeloma, and subsequently approved for treatment of MCL. BTZ’s single-agent...
Spremljeno u:
| Izdano u: | Expert Opin Drug Discov |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5520581/ https://ncbi.nlm.nih.gov/pubmed/27917682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17460441.2017.1268596 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|